For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Background This study aimed to systematically evaluate and compare the efficacy and
safety of consolidative hematopoietic stem cell transplantation (HSCT) after CD19 chimeric …

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …

Detectable measurable residual disease (MRD) is a key prognostic factor in both acute
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we …

Background Consolidative allogeneic hematopoietic stem cell transplantation is a
controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after …

Allogeneic blood or marrow transplantation (alloBMT) is standard of care for adults with
Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in first …

Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial
complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients …

The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with
acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) …

Background The aim of this study was to compare two immunosuppressive strategies, based
on the use of either rabbit antithymocyte globulin (ATG) or posttransplant cyclophosphamide …

In this registry-based study we retrospectively compared outcomes of allogeneic
hematopoietic cell transplantation (allo-HCT) for adult patients with acute lymphoblastic …